ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer.
Contemp Clin Trials Commun
; 30: 101036, 2022 Dec.
Article
em En
| MEDLINE
| ID: mdl-36407843
Analgesics; BFI, Bowel Function Index; BPI SF, Brief Pain Inventory Short Form; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration calculation; Constipation; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; GEE, Generalised Estimating Equations; ITT, Intention To Treat; Neoplasms; OIC, opioid-induced constipation; OXN PR, oxycodone/naloxone prolonged release; Opioid; Oxy PR, oxycodone prolonged release; PRO CoMiDa, Patient Reported Outcome Completion and Missing Data Checklist; PRO, Patient Reported Outcome; Pain; Palliative care; S-LANSS, Leeds Assessment of Neuropathic Symptoms & Signs
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article